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OBJECTIVES: Sacral Nerve Modulation (SNM) is a minimally-invasive technology
indicated for overactive bladder (OAB). SNM efficacy has been widely demonstrated
yet its cost-effectiveness in the UK is unknown. The cost-effectiveness of SNM in
patients with refractory idiopathic OAB with urinary incontinence (OAB-wet) was
compared to optimal medical therapy (OMT), Botulinum Toxin A (BoNT-A) and
PTNS from the UK NHS perspective.METHODS:A published Spanish Markov model
was adapted to current UK practice based on existing data and clinical expert
advice. Treatment success was defined as 50% improvement in OAB-wet symp-
toms. Health care resource use included pre-,peri-, and post-procedure; drugs;
follow-ups and adverse events. Both SNM using testing with tined-lead (SNM-
tined-lead) and PNE (SNM-PNE) were evaluated. Incremental-cost-effectiveness-
ratios (ICER;costs per quality-adjusted-life-year)were calculated for SNM vs. OMT
and vs. BoNT-A (10yrs), and SNM vs, PTNS (5yrs); with uni-variate sensitivity
analyses.RESULTS:At 10 years, the cumulative costs of SNM-tined-lead, SNM-PNE,
BoNT-A and OMT were £22,052, £19,952, £18,477, £11,918, respectively; PTNS 5-year
cumulative costs were £17,915.The QALYs for SNM-tined-lead, SNM-PNE, BoNT-A
and OMT were 6.82, 6.64, 6.35 and 5.45 (10yrs), respectively, and 3.44 for PTNS (5yrs).
ICERs were £7,608 and £7,356 for SNM-tined-lead vs. BoNT-A, and vs OMT (10yrs),
respectively; SNM-tined-lead and SNM-PNE were dominant (less costly and more
effective) compared to PTNS (5 years). SNM- tined-lead was cost-effective vs.SNM-
PNE. ICERs were most sensitive to BoNT-A efficacy and costs, but results were
generally robust. CONCLUSIONS: SNM in patients with OAB-wet provides addi-
tional quality of life improvement with higher initial costs for SNM that are offset
by a reduction in follow-up costs over time. This produces ICERs that are clearly
below the threshold generally considered for cost-effectiveness in the UK. SNM
represents value for money compared to OMT, BoNT-A and PTNS, and may be
considered the preferred treatment option in the UK.
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OBJECTIVES: In patients with one to four brain metastasis, if diameter  4 cm, the
standard treatment is whole brain irradiation (WBI) followed by stereotactic radio-
surgery (SRS). There is growing interest on the delivery of isolated SRS, aiming to
reduce side effects of WBI, despite a higher risk of intra-cerebral recurrences. The
objective of this study was to compare the cost-effectiveness of those two strate-
gies, under Brazilians third-part payers’ perspective. METHODS: A meta-analysis
of summary data, including all phase III prospective trails that compared SRS to
WBISRS, was performed. Data about recurrence management, dependant of on
the lesion size, as well as of previous delivered treatment, were also extracted.
Costs were estimated based on charges accordingly to Brazilian Health Care reim-
bursement rates for the private system (CBHPM). Only directs costs were consid-
ered, and were expressed in Brazilian Reais (BRL). A probabilistic sensitivity anal-
ysis was conducted to evaluate the robustness of the results. The perspective was
that from the Brazilian Third Party payer. RESULTS: Three phase III prospective
trials have been selected, including 467 patients. Once there was no difference in
overall survival, effectiveness was evaluated according to local control. After two
years of follow up, 78% [64.2-87.4%] of the SRS patients and 53% [47-57%] of the
WBISRS patients have recurred. The incremental cost-effectiveness ratio (ICER)
comparing WBISRS to SRS was of 7.489,60 BRL/year without cerebral recurrences.
Sensitivity analysis showed that ICER remains acceptable under a wide range of
assumptions . CONCLUSIONS: Results suggested that WBISRS might be consid-
ered as a cost-effective strategy in patients with up to 4 brain metastases. Once no
detrimental survival effect have been shown, SRS can be cost-savings for Brazilians
third-party payers, but patients need to be aware of the risks involved in not deliv-
ering WBI.
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OBJECTIVES: To assess the cost-effectiveness of 3M™ Coban™2 Layer Compres-
sion System (Coban 2) for the treatment of venous leg ulcers in the Dutch health
care setting. METHODS: The health economic evaluation consists of a cost-effec-
tiveness analysis. A Markov model was developed in order to determine the cost-
effectiveness of Coban 2, which was based on different health states and allowed
transitions between these states. Upon initiation of the compression system Coban
2, the patient is supposed to have an ulcer. Over time, the ulcer may heal, but it may
also recur. The treatment with Coban 2 is compared with traditional treatment
(Short Stretch Bandages (SSB)). The primary perspective of the study is that of the
Dutch insurer in 2012. The actual costs, which are included in the study, are prod-
uct costs and treatment costs. Clinical probabilities on healing and recurrence are
derived from clinical published literature. RESULTS: The use of Coban 2 leads to a
total cost of € 600 compared to € 2,663 for traditional care, which leads to cost saving
of € 2,063 per patient over a period of 1 year. The effectiveness for Coban 2 is 84.5%
time without symptoms; the effectiveness for traditional care is 65.0% time with-
out symptoms, which is leading to a gain of 2.3 months without symptoms over
period of 1 year. CONCLUSIONS: The use of Coban 2 versus traditional treatment is
cost-effective, because it is cost saving in combination with a higher effectiveness.
As a consequence the cost savings by Coban 2 also translates into a positive impact
on total health care budget.
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OBJECTIVES: This study evaluated the cost-effectiveness of three leprosy case de-
tection methods in Northern Nigeria to identify the most cost-effective approach to
new case detection for improved leprosy control in Nigeria. METHODS: A cross-
sectional study was carried out to evaluate the additional benefits of using several
case detection methods in addition to routine practice in two north-eastern states
of Nigeria. Primary and secondary data were collected from routine practice re-
cords and the Nigerian Tuberculosis and Leprosy Control Programme of 2009.
Methods evaluated were Rapid Village Survey (RVS), Household Contact Examina-
tion (HCE) and Traditional Healers incentive method (TH). Effectiveness was mea-
sured as number of new leprosy cases detected and cost-effectiveness was ex-
pressed as cost per case detected. Costs were measured from both providers’ and
patients’ perspectives. Additional costs and effects of each method were estimated
by comparing each method against routine practise and expressed as incremental
cost-effectiveness ratio (ICER). All costs were converted to the US Dollar at the 2010
exchange rate. Univariate sensitivity analysis was used to evaluate uncertainties
around the ICER. RESULTS: The ICER for HCE was $142 per additional case detected
at all contact levels and it was the most cost-effective method. At ICER of $194 per
additional case detected, THs method detected more cases at a lower cost than the
RVS which was not cost-effective at $313 per additional case detected. Sensitivity
analysis showed that varying the proportion of shared costs and subsistent wage
for valuing unpaid time did not significantly change the results. CONCLUSIONS:
Complementing routine practice with household contact examination is the most
cost-effective approach to identify new leprosy cases and we recommend that,
depending on acceptability and feasibility, this intervention is introduced for im-
proved case detection in Northern Nigeria.
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OBJECTIVES: To assess the cost-effectiveness of 3M™ CobanTM2 Layer Compres-
sion System (Coban 2) for the treatment of lymphoedema in the Dutch health care
setting. METHODS: The health economic evaluation consists of a cost-effective-
ness analysis. A decision tree model was developed in order to determine the
cost-effectiveness of Coban 2. The entry point of the model consists of patients
with lymphoedema requiring treatment with compression bandages. The treat-
ment with Coban 2 is compared with traditional treatment (Short Stretch Ban-
dages). The primary perspective of the study is that of the Dutch insurer in 2012.
The actual costs, which are included in the study, are product costs and treatment
costs. RESULTS: The use of Coban 2 leads to a mean total cost of € 528 compared to
€ 630 for traditional care, which leads to a cost saving of € 102 per patient. The
effectiveness for Coban 2 is higher because of a shorter treatment period, which
leads to a reduction of the negative impact on Quality of life by lymphoedema.
CONCLUSIONS: The use of Coban 2 versus traditional treatment is cost saving for
each treatment period with a higher effectiveness, due to shorter treatment dura-
tion and improvement in Quality of Life. As a consequence the use of Coban 2 leads
to a positive impact on the total health care budget.
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OBJECTIVES: Functional imaging with positron emission tomography (PET) is a
promising non-invasive modality in the clinical management of squamous cell
carcinoma of the head and neck (SCCHN). Currently, there is limited evidence that
points to the potential cost-effectiveness of PET in this setting. The objective of this
study was to assess the methodological quality of cost-effectiveness analyses
(CEAs) of PET in SCCHN. METHODS: A systematic literature review was performed
focusing on CEAs of PET in SCCHN using MEDLINE, EMBASE, NHS EED and the CEA
Registry. Studies were screened according to a priori eligibility criteria. The meth-
odological quality of the primary clinical studies was examined by QUality Assess-
ment of Diagnostic Accuracy Studies checklist. CEAs were critically appraised us-
ing the Drummond checklist. RESULTS: A total of seven studies met the inclusion
criteria. PET or computed tomography (CT) integrated with PET was assessed in two
indications: detection of recurrent disease and screening for metastasis. In each
indication, PET strategy ranged from likely to be cost-effective (in four studies) to
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likely to be cost-saving (in three studies). Prevalence of disease, diagnostic accu-
racy and cost of PET were the most influential variables. Ranges for sensitivity,
specificity and the cost of PET were 53%-100%, 82%-95% and €787-€1,225, respec-
tively. Sources of bias in the diagnostic accuracy studies were mainly related to the
representative patient population and interpretation of the index test and refer-
ence case. Critical assessment of the CEAs revealed that issues of documentation,
feasibility of adopting PET in daily practice and generalizability were key areas that
affected quality.CONCLUSIONS: PET, as a reliable diagnostic tool, has the potential
to improve disease detection and avoid futile procedures that can lead to morbidity
and high costs. Given the limitations of the existing studies, future CEAs should
prospectively explore the expanding applications and cost-effectiveness of PET in
SCCHN.
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OBJECTIVES: The majority of bowel disorders exhibit a limited number of overlap-
ping symptoms, making diagnosis very difficult in primary care. The inflammatory
bowel diseases (IBD) are characterized by chronic inflammation of the gastrointes-
tinal tract; the irritable bowel syndrome (IBS) is a functional disorder, with preva-
lence 10%-20% (Bellini, 2011). Endoscopy is considered as the gold standard proce-
dure for detecting and quantifying IBDs, but due to the low prevalence of IBD
(Molodecky, 2012), it turns negative in most of the cases, it is expensive, uncom-
fortable and risky for the patient. F-Calprotectin is a faecal marker of intestine
inflammation; IBD patients exhibit F-Calprotectin levels significantly higher than
the general population; IBS patients have F-Calprotectin levels significantly lower
than IBD patients. Therefore, F-Calprotectin can be used as a pre-endoscopic tech-
nique to differentiate between IBD and IBS. We aim at evaluating the cost-effec-
tiveness of F-Calprotectin tests compared to the standard pre-endoscopic tests
(combined usage of serologic markers CRP - C-reactive protein - and ESR - erythro-
cyte sedimentation rate) to distinguish IBD from IBS in selected European markets
(UK, SW, FR). METHODS: F-Calprotectin and CRPESR test accuracy was evaluated
on existing data; the costs (diagnostic tests, diet, medications, and indirect costs)
were collected from the literature. The analysis was tailored to children, teenagers
and adults. The outcomes include cost avoidance, cost per corrected IBD diag-
nosed, and endoscopies reduction. Uncertainty was addressed with sensitivity
analysis. RESULTS: Results show that the usage of F-Calprotectin is cost-effective
with respect to CRPESR: a) it results in more corrected IBD diagnoses at a lower
price (in UK it costs £50 less per adult patient than CRPESR), b) it reduces the
number of unnecessary endoscopies. CONCLUSIONS: F-Calprotectin is a cost-ef-
fective methodology to rule out IBD at the primary care level, and it has a higher
accuracy than CRPESR.
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OBJECTIVES: Cardiac resynchronization therapy with biventricular pacemaker
(CRT-P) is considered an effective treatment for heart failure (HF). Adding implant-
able cardioverter defibrillators (CRT-D) may further reduce the risk of sudden car-
diac death (SCD). However, economic evaluations have shown that incremental
cost-effectiveness ratios (ICERs) of CRT-D may be substantially higher than for
comparators, due to large numbers of patients which do not get additional benefits
from CRT-D. Therefore, current research, like ‘Biomarkers to predict cardiac fail-
ure, arrhythmias and success of treatment’ (COHFAR), is trying to identify a set of
(bio)markers that predict the response to CRT-D. The objective of this study was to
review full economic models evaluating implantable CRT-D for patients with HF,
compare the structure and inputs of the cost-effectiveness models and identify the
main factors influencing the ICERs for CRT-D. METHODS: A comprehensive search
strategy of PubMed, Embase, Web of Science identified six full economic models
evaluating CRT-D against optimal pharmacological therapy (OPT) and/or CRT-P. All
studies included a Markov or other state transition model for the long term fol-
low-up of the HF patients. Four studies included a comparison of CRT-D with CRT-P
while two others compared CRT-D with OPT. RESULTS: Studies differed in terms of
time horizons and comparators. The inputs for the models were mainly taken from
two trials, only one of which compared CRT-D and CRT-P to OPT. Generally, CRT-D
was found cost-effective when compared to OPT but its cost-effectiveness became
questionable when compared to CRT-P. This depended on cost of devices, mortal-
ity due to SCD and battery longevity. CONCLUSIONS: A better identification of
patients that are more likely to benefit from CRT-D (i.e. those with higher risks of
SCDs) will certainly have an effect on the cost-effectiveness of this technology in
comparison to CRT-P.
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OBJECTIVES: Sensitization to pollen is common in the Mediterranean Area, and
patients are frequently treated with allergen-specific immunotherapy (SIT); in SIT
the precise identification of the disease-eliciting allergen is a requisite for long-
lasting therapeutic effect. SIT is prescribed following the EAACI Guidelines using
skin prick test (SPT) (Alvarez-Cuesta, 2006). Nowadays, molecular allergology (MA)
gives more accurate information about the true patient sensitization, and the use-
fulness of adding MA to SPT for SIT-indication is demonstrated in (Sastre, 2012).
Non-adherence to SIT is a major hurdle, contributing to poor clinical outcomes:
39% of pediatric patients receive SIT for less than 6 months and only 16% for 3
years (Hankin, 2008; similar data for adults in Senna, 2010). In this study, we ana-
lyze this multi-dimensional phenomenon merging all the measures available in
the literature in one HE model: 1) data on high inaccuracy of guideline-based diag-
nostics (Sastre); with 2) the hypothesis of improvements by MA; with 3) QoL mea-
sures from (Ciprandi, 2010); with 4) SIT-adherence (Hankin and Senna); with 5) SIT
monitoring by MA. METHODS: A total of 141 patients with allergic rhino-conjunc-
tivitis and/or asthma sensitized to pollen from a complex pollen area (Spain) were
SPT tested, and subsequently MA was performed using a microarray-based panel
of 96 allergens (ImmunoCap ISAC®). The model covers a 3-year timeframe; the
outcomes include the number of SITs correctly prescribed, and cost-effectiveness
(CE). Uncertainty was addressed with sensitivity analysis. RESULTS: Results show
that adding MA to SPT reduces SIT prescriptions by at least 20% (substantial costs
saving), and allows for a more targeted (i.e. more successful with a higher QoL) SIT.
CONCLUSIONS: Our results based on available data from multiple studies show
that MA usage for SIT prescription is CE, and can increase SIT-adherence. We
recommend a clinical trial capturing all the multi-dimensional aspects of this phe-
nomenon should be conducted for model validation purposes.
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OBJECTIVES: Abdominal aortic aneurysm (AAA) is a chronic, progressive disease
that often requires surgical repair. The risk of rupture and death both increase with
the size of the aneurysm. Scanning patients to identify the presence of an aneu-
rysm and monitoring its growth is an important diagnostic practice for managing
these patients. The present study investigates whether the use of a portable hand
held device is cost effective in a hypothetical population of 10,000 (e.g., 65 years of
age) male subjects with a history of smoking who would otherwise not be screened
for AAA. METHODS: The study performed cost utility analysis, developing a sim-
ulation model that compared the incremental cost per quality-adjusted life year
gained for four alternative scenarios. Scenario I received no scanning and Scenar-
ios II – IV differed on what size AAA was to be treated if detected. Model input
values were taken from the literature. The screened scenarios differ in terms of the
size at which aneurysms were treated surgically. RESULTS: The total expected
costs were: $20.4 million, $33.2 million, $19.8 million, and $18.7 million for Scenar-
ios I to IV respectively. The total expected deaths were: 72, 39, 50, and 58 for Sce-
narios I to IV respectively. The incremental cost effectiveness ratio for Scenario II
vs. Scenario I was $64,160. Compared to Scenario I, Scenario III and IV were
dominant. CONCLUSIONS: Under all of the treatment arms, the use of the handheld
scanning device was cost effective relative to the Scenario I cohort. Treating patients with
medium or large aneurysms (Scenario III) or just large aneurysms (Scenario IV), substan-
tially enhances the cost effectiveness. These results suggest that primary care physicians
should consider this device as a cost effective method to identify and treat AAA patients
among male patients who are elderly and have a history of smoking.
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OBJECTIVES: Implantable ports (IPs) are widely used in therapeutic areas where
frequent vascular accesses are required. The use of IPs represents a practical solu-
tion and offers comfort to patients; however it is associated with significant ob-
struction rate, which may lead to high hospital costs. Single-hand secured Huber
needles (SSHNs) are designed to reduce the frequency of catheter obstructions
compared to two-hand Huber needles (THNs).To assess the economic and organi-
zational impact of the systematic use of SSHN from a hospital perspective, a deci-
sion tree model was designed.METHODS:Resource consumptions and costs (Euros
2012) associated with the systematic use of SSHN and THN were collected in French
hospitals of Paris area (AP-HP). Both strategies were evaluated along the reperfu-
sion process (when it occurred). Probabilities of obstruction were extracted from
published literature and estimated by experts when not available. Deterministic
and probabilistic sensitivity analyses (DSA and PSA) were performed to appraise
the uncertainty around estimated parameters; RESULTS: The simulation showed
that the systematic use of SSHN is associated with lower hospital expenses com-
pared to THN. Based on the use of 10,000 needles per year, its systematic use would
save €27,360 annually (total cost of €147,540 versus €174,897). In particular, a total of
€16,259 related to consumables and medical procedures would be directly saved
from hospital budget. The remaining part would result in 0.13 nursing full-time
equivalent (FTE) and 0.03 medical FTE, which could be reallocated to other activi-
ties. DSA showed that baseline obstruction rate is the most influential variable for
annual cost and PSA confirmed that SSHN is the least expensive strategy.
CONCLUSIONS: The reduction of use of consumables derived from the model was
in line with observations in AP-HP. The systematic use of SSHN would probably
lead to a reduction in expenses for hospitals, and staff time saved.
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